{"id":"https://openalex.org/W4366606586","doi":"https://doi.org/10.1016/j.ophtha.2023.04.012","title":"One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS\u00ae Registry","display_name":"One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS\u00ae Registry","publication_year":2023,"publication_date":"2023-04-21","ids":{"openalex":"https://openalex.org/W4366606586","doi":"https://doi.org/10.1016/j.ophtha.2023.04.012","pmid":"https://pubmed.ncbi.nlm.nih.gov/37086857"},"language":"en","primary_location":{"id":"doi:10.1016/j.ophtha.2023.04.012","doi":"https://doi.org/10.1016/j.ophtha.2023.04.012","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ophtha.2023.04.012","pdf_url":null,"source":{"id":"https://openalex.org/S207341048","display_name":"Ophthalmology","issn_l":"0161-6420","issn":["0161-6420","1549-4713"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091082221","display_name":"Mathew W. MacCumber","orcid":"https://orcid.org/0000-0003-1063-1124","observed_orcids":["https://orcid.org/0000-0003-1063-1124"]},"institutions":[{"id":"https://openalex.org/I1285301757","display_name":"Rush University Medical Center","ror":"https://ror.org/01j7c0b24","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285301757"]},{"id":"https://openalex.org/I4210156013","display_name":"Illinois Retina Associates","ror":"https://ror.org/05czd8n07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210156013"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mathew W. MacCumber","raw_affiliation_strings":["Department of Ophthalmology, Rush University Medical Center, Chicago, and Illinois Retina Associates SC, Harvey, Illinois. Electronic address: mmaccumber@illinoisretina.com","Department of Ophthalmology, Rush University Medical Center, Chicago, and Illinois Retina Associates SC, Harvey, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Ophthalmology, Rush University Medical Center, Chicago, and Illinois Retina Associates SC, Harvey, Illinois. Electronic address: mmaccumber@illinoisretina.com","institution_ids":["https://openalex.org/I1285301757","https://openalex.org/I4210156013"]},{"raw_affiliation_string":"Department of Ophthalmology, Rush University Medical Center, Chicago, and Illinois Retina Associates SC, Harvey, Illinois","institution_ids":["https://openalex.org/I1285301757","https://openalex.org/I4210156013"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051960536","display_name":"Charles C. Wykoff","orcid":"https://orcid.org/0000-0001-7756-5091","observed_orcids":["https://orcid.org/0000-0001-7756-5091"]},"institutions":[{"id":"https://openalex.org/I4210094205","display_name":"Retina Consultants of Texas","ror":"https://ror.org/00j7qa995","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210094205"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles C. Wykoff","raw_affiliation_strings":["Retinal Consultants of Texas, Houston, Texas"],"raw_orcid":"https://orcid.org/0000-0001-7756-5091","affiliations":[{"raw_affiliation_string":"Retinal Consultants of Texas, Houston, Texas","institution_ids":["https://openalex.org/I4210094205"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040904403","display_name":"H\u00e9l\u00e8ne Karcher","orcid":"https://orcid.org/0000-0003-0798-4084","observed_orcids":["https://orcid.org/0000-0003-0798-4084"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Helene Karcher","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":"https://orcid.org/0000-0003-0798-4084","affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068903823","display_name":"Eser Adiguzel","orcid":"https://orcid.org/0000-0003-2700-5808","observed_orcids":["https://orcid.org/0000-0003-2700-5808"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eser Adiguzel","raw_affiliation_strings":["Novartis Pharmaceuticals Corp., East Hanover, New Jersey"],"raw_orcid":"https://orcid.org/0000-0003-2700-5808","affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corp., East Hanover, New Jersey","institution_ids":["https://openalex.org/I4210117619"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035558686","display_name":"Samriddhi Buxy Sinha","orcid":"https://orcid.org/0000-0001-7807-9570","observed_orcids":["https://orcid.org/0000-0001-7807-9570"]},"institutions":[{"id":"https://openalex.org/I4388891806","display_name":"Sandoz Group AG (Switzerland)","ror":"https://ror.org/02rse7p59","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4388891806"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Samriddhi Buxy Sinha","raw_affiliation_strings":["Sandoz (Novartis), Basel, Switzerland"],"raw_orcid":"https://orcid.org/0000-0001-7807-9570","affiliations":[{"raw_affiliation_string":"Sandoz (Novartis), Basel, Switzerland","institution_ids":["https://openalex.org/I4388891806"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048715505","display_name":"Saloni Vishwakarma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Saloni Vishwakarma","raw_affiliation_strings":["Verana Health, Inc., San Francisco, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Verana Health, Inc., San Francisco, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060621511","display_name":"Andrew LaPrise","orcid":"https://orcid.org/0000-0003-3717-1279","observed_orcids":["https://orcid.org/0000-0003-3717-1279"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew LaPrise","raw_affiliation_strings":["Verana Health, Inc., San Francisco, California"],"raw_orcid":"https://orcid.org/0000-0003-3717-1279","affiliations":[{"raw_affiliation_string":"Verana Health, Inc., San Francisco, California","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019577901","display_name":"Franklin Igwe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Franklin Igwe","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040630911","display_name":"Rita L. Freitas","orcid":"https://orcid.org/0000-0003-1145-6444","observed_orcids":["https://orcid.org/0000-0003-1145-6444"]},"institutions":[{"id":"https://openalex.org/I4403386565","display_name":"Novartis Farma SA (Portugal)","ror":"https://ror.org/03fjwdh27","country_code":"PT","type":"company","lineage":["https://openalex.org/I4403386565"]}],"countries":["PT"],"is_corresponding":false,"raw_author_name":"Rita Freitas","raw_affiliation_strings":["Novartis Farma-Produtos Farmac\u00eauticos S.A., Porto Salvo, Portugal"],"raw_orcid":"https://orcid.org/0000-0003-1145-6444","affiliations":[{"raw_affiliation_string":"Novartis Farma-Produtos Farmac\u00eauticos S.A., Porto Salvo, Portugal","institution_ids":["https://openalex.org/I4403386565"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017043678","display_name":"Michael S. Ip","orcid":"https://orcid.org/0000-0003-1304-4101","observed_orcids":["https://orcid.org/0000-0003-1304-4101"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]},{"id":"https://openalex.org/I4210095445","display_name":"Doheny Eye Institute","ror":"https://ror.org/00qvx5329","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210095445"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael S. Ip","raw_affiliation_strings":["Doheny Eye Institute, University of California, Los Angeles, Los Angeles, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Doheny Eye Institute, University of California, Los Angeles, Los Angeles, California","institution_ids":["https://openalex.org/I161318765","https://openalex.org/I4210095445"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5058961724","display_name":"Marco A. Zarbin","orcid":"https://orcid.org/0000-0002-7811-7132","observed_orcids":["https://orcid.org/0000-0002-7811-7132"]},"institutions":[{"id":"https://openalex.org/I4402554120","display_name":"Rutgers New Jersey Medical School","ror":"https://ror.org/014ye1258","country_code":"US","type":"education","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4402554120"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marco A. Zarbin","raw_affiliation_strings":["Department of Ophthalmology and Visual Science, Rutgers-New Jersey Medical School, Newark, New Jersey"],"raw_orcid":"https://orcid.org/0000-0002-7811-7132","affiliations":[{"raw_affiliation_string":"Department of Ophthalmology and Visual Science, Rutgers-New Jersey Medical School, Newark, New Jersey","institution_ids":["https://openalex.org/I4402554120"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5091082221"],"corresponding_institution_ids":["https://openalex.org/I1285301757","https://openalex.org/I4210156013"],"apc_list":{"value":4170,"currency":"USD","value_usd":4170},"apc_paid":null,"fwci":4.0919,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.94806993,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"130","issue":"9","first_page":"937","last_page":"946"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11377","display_name":"Retinal and Macular Surgery","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brolucizumab","display_name":"brolucizumab","score":0.9789999723434448},{"id":"https://openalex.org/keywords/neovascular-age-related-macular-degeneration","display_name":"neovascular age-related macular degeneration","score":0.9990000128746033},{"id":"https://openalex.org/keywords/visual-acuity-outcomes","display_name":"visual acuity outcomes","score":0.800000011920929},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.859000027179718},{"id":"https://openalex.org/keywords/treatment-naive-eyes","display_name":"treatment-naive eyes","score":0.6570000052452087},{"id":"https://openalex.org/keywords/injection-interval","display_name":"injection interval","score":0.703000009059906},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6380000114440918},{"id":"https://openalex.org/keywords/iris-registry","display_name":"IRIS Registry","score":0.6110000014305115},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.6019999980926514}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9680516719818115},{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.8205307126045227},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.638502299785614},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.5694437623023987},{"id":"https://openalex.org/C2778257484","wikidata":"https://www.wikidata.org/wiki/Q555066","display_name":"Visual acuity","level":2,"score":0.5674374103546143},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5418352484703064},{"id":"https://openalex.org/C2779829184","wikidata":"https://www.wikidata.org/wiki/Q631361","display_name":"Diabetic retinopathy","level":3,"score":0.49380549788475037},{"id":"https://openalex.org/C2781359195","wikidata":"https://www.wikidata.org/wiki/Q5105209","display_name":"Choroidal neovascularization","level":3,"score":0.48663219809532166},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.44546547532081604},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4302576780319214},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.42920345067977905},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4098787307739258},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20969483256340027},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.10591062903404236},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012042","descriptor_name":"Registries","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057135","descriptor_name":"Wet Macular Degeneration","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D057135","descriptor_name":"Wet Macular Degeneration","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D057135","descriptor_name":"Wet Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D058449","descriptor_name":"Intravitreal Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.ophtha.2023.04.012","doi":"https://doi.org/10.1016/j.ophtha.2023.04.012","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.ophtha.2023.04.012","pdf_url":null,"source":{"id":"https://openalex.org/S207341048","display_name":"Ophthalmology","issn_l":"0161-6420","issn":["0161-6420","1549-4713"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"journal-article"},{"id":"pmid:37086857","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37086857","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"Observational Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W1993399691","https://openalex.org/W2619267093","https://openalex.org/W2784031367","https://openalex.org/W2936430874","https://openalex.org/W2963553144","https://openalex.org/W2988938511","https://openalex.org/W3035836792","https://openalex.org/W3090861539","https://openalex.org/W3101914433","https://openalex.org/W3127081644","https://openalex.org/W3139128085","https://openalex.org/W3155919247","https://openalex.org/W3166314067","https://openalex.org/W3200362086","https://openalex.org/W3216938625","https://openalex.org/W4200460276","https://openalex.org/W4214901362","https://openalex.org/W4220790233","https://openalex.org/W4220809943","https://openalex.org/W4224605637","https://openalex.org/W4229336372","https://openalex.org/W4252400934","https://openalex.org/W4280579412","https://openalex.org/W4281251314","https://openalex.org/W4281251987","https://openalex.org/W4281618856","https://openalex.org/W4281770854","https://openalex.org/W4296325221","https://openalex.org/W4306729289","https://openalex.org/W4308061198","https://openalex.org/W4318913856","https://openalex.org/W4361000164","https://openalex.org/W6795738664"],"related_works":["https://openalex.org/W4318913856","https://openalex.org/W4388914765","https://openalex.org/W3131686561","https://openalex.org/W4391353383","https://openalex.org/W4393118862","https://openalex.org/W3166314067","https://openalex.org/W4364356188","https://openalex.org/W4361000164","https://openalex.org/W6910616924","https://openalex.org/W4411061835"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-04-23T00:00:00"}